$XXII they were going to run out in October. This easily gets them through key FDA decision in Q4. Strong raise on excellent terms all things considered. They needed cash bad. IMO it was already priced into the stock at .80. Looks like I had that right.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.